New approach for delivery of anti-HIV antibody therapy shows promise in phase I clinical trial
Treatment using adeno-associated viral vector is poised to move into larger, later-phase trials.
Press Release5 Minute ReadDec | 15 | 2020
Facundo Batista, PhDWith the recent advances in gene editing technology like CRISPR/Cas9, we knew there had to be a way to speed up this process significantly.
BOSTON -- To develop vaccines and investigate human immune responses, scientists rely on a variety of animal models, including mice that can produce human antibodies through genetically engineered B cell receptors, which are specialized antibodies bound to the B cell membrane. These mice, however, often take several years to develop, requiring a complicated process of genetic modification and careful breeding.
“The time it takes to generate these specialized mice has been a major factor in delaying vaccine development,” says Facundo Batista, PhD, associate director of the Ragon Institute of MGH, MIT and Harvard. “With the recent advances in gene editing technology like CRISPR/Cas9, we knew there had to be a way to speed up this process significantly.”
Batista’s group has developed a new method for generating mouse lines for pre-clinical vaccine evaluation that dramatically shortens this timeline. In a study published recently in the journal EMBO, this one-step method, which uses CRISPR/Cas9 technology, can produce mice with genetically engineered human B cell receptors in just a few weeks.
To test this technology, the researchers engineered mice to have human B cell receptors that are precursors to what are called broadly neutralizing HIV antibodies. These antibodies are known to be effective in combating HIV, but they are difficult to stimulate through vaccination. The precursors responded to an antigen currently being used in clinical HIV trials by generating broadly neutralizing antibody–like mutations. The ability to quickly evaluate the ability of different antigens to active these precursors has the potential to significantly accelerate vaccine development.
The engineered B cells were not just capable of making high-quality antibodies; some became a specialized form of B cell known as memory B cells, which are used to maintain long-lasting immunity once antibodies are produced against a pathogen. This means the mice can likely be used to quickly validate good candidate vaccines for HIV and other pathogens.
“This new technique may allow scientists studying vaccines and antibody evolution to tremendously speed up their research,” says Ragon research fellow Xuesong Wang, PhD, co-first author on the paper.
Rashmi Ray, PhD, also co-first author and a Ragon research fellow, agrees: “It will allow researchers to respond much more quickly and flexibly to new developments in the field.”
About the Ragon Institute of MGH, MIT and Harvard
The Ragon Institute of MGH, MIT and Harvard was established in 2009 with a gift from the Phillip T. and Susan M. Ragon Foundation, with a collaborative scientific mission among these institutions to harness the immune system to combat and cure human diseases. Focusing on global infectious diseases, the Ragon Institute draws scientists, clinicians and engineers from diverse backgrounds and areas of expertise to study and understand the immune system with the goal of benefiting patients. For more information, visit www.ragoninstitute.org
Treatment using adeno-associated viral vector is poised to move into larger, later-phase trials.
Insights may lead to more effective treatments for bacterial vaginosis and improve women’s health outcomes globally.
Mass General Brigham is proud to announce the award of $6 million to 35 organizations dedicated to improving both mental and behavioral health outcomes, as well as promoting economic mobility and financial stability in the communities we serve.
Massachusetts General Hospital, part of the Mass General Brigham healthcare system, announced that $18 million in Community Health Impact Funds have been awarded to 22 local organizations to support affordable housing initiatives in Boston and North Suffolk County.
Study examines maternal immune responses and antibody transfer from mother to fetus for different vaccines across pregnancy trimesters.
Researchers uncover how the immune system clears, or in some cases helps, bacteria after infection.
Treatment using adeno-associated viral vector is poised to move into larger, later-phase trials.
Insights may lead to more effective treatments for bacterial vaginosis and improve women’s health outcomes globally.
Mass General Brigham is proud to announce the award of $6 million to 35 organizations dedicated to improving both mental and behavioral health outcomes, as well as promoting economic mobility and financial stability in the communities we serve.
Massachusetts General Hospital, part of the Mass General Brigham healthcare system, announced that $18 million in Community Health Impact Funds have been awarded to 22 local organizations to support affordable housing initiatives in Boston and North Suffolk County.